Glycosylation: impact, control and improvement during therapeutic protein production
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The emergence of the biopharmaceutical industry represented a major revolution for modern medicine, through the development of recombinant therapeutic proteins that brought new hope for many patients with previously untreatable diseases. There is a ever-growing demand for these therapeutics that forces a constant technological evolution to increase product yields while simultaneously reducing costs. However, the process changes made for this purpose may also affect the quality of the product, a factor that was initially overlooked but which is now a major focus of concern. Of the many properties determining product quality, glycosylation is regarded as one of the most important, influencing, for example, the biological activity, serum half-life and immunogenicity of the protein. Consequently, monitoring and control of glycosylation is now critical in biopharmaceutical manufacturing and a requirement of regulatory agencies. A rapid evolution is being observed in this context, concerning the influence of glycosylation in the efficacy of different therapeutic proteins, the impact on glycosylation of a diversity of parameters/processes involved in therapeutic protein production, the analytical methodologies employed for glycosylation monitoring and control, as well as strategies that are being explored to use this property to improve therapeutic protein efficacy (glycoengineering). This work reviews the main findings on these subjects, providing an up-to-date source of information to support further studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Electrospray Ionization for Mass Spectrometry of Large Biomolecules
Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F., & Whitehouse, C. M. (1989) · Science · doi:10.1126/science.2675315 · Cited by 7,634 · cited 1×
“ESI-MS provides data that can be interpreted to determine monosaccharide linkage and position (Fenn et al., 1989).”
BackgroundIntracellular Functions of N-Linked Glycans
Helenius, A., & Aebi, A. M. (2001) · Science · doi:10.1126/science.291.5512.2364 · Cited by 2,405 · cited 2×
“The attachment of glycans to some proteins (e.g. erythropoietin) also aids in folding (Helenius & Aebi, 2001; Narhi et al., 1991).”
BackgroundProduction of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835 · cited 10×
“In contrast to other glycoproteins, where higher contents of sialic acid result in extended circulatory half-life and improved efficacy, increased levels of sialylation have an adverse effect on mAb efficacy by reducing ADCC activity (Scallon et al., 2007).”
BackgroundInfluentialAnti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413 · cited 4×
“…of a knockout CHO cell line that produces completely defucosylated mAbs (Natsume et al., 2009; Yamane-Ohnuki et al., 2004), which exhibit enhanced ADCC (Masuda et al., 2007; Satoh et al., 2006) and achieve therapeutic efficacy at low doses (Shinkawa et al., 2003; Yamane-Ohnuki et al., 2004).”
BackgroundInfluentialBaculovirus as versatile vectors for protein expression in insect and mammalian cells
Kost, T. A., Condreay, J. P., & Jarvis, D. L. (2005) · Nature Biotechnology · doi:10.1038/nbt1095 · Cited by 1,014
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · cited 4×
“functions through the modulation of the binding affinities for FcgR receptors (Crispin et al., 2009; Jefferis, 2009a; Li & d’Anjou, 2009; Mimura et al., 2009; Raju, 2008).”
BackgroundInfluentialUmaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764 · cited 3×
“…ADCC can be accomplished by the attachment of bisecting GlcNAc, an effect that has been attributed to the low Fuc content associated with this residue (the bisecting GlcNAc inhibits further addition of Fuc during biosynthesis) (Abès & Teillaud, 2010; Ferrara et al., 2006b; Umana et al., 1999).”
Background
Cited by
Recent advances in (therapeutic protein) drug development
Lagassé, H. A. D., Alexaki, A., Simhadri, V. L., Katagiri, N. H., Jankowski, W., Sauna, Z. E., & Kimchi-Sarfaty, C. (2017) · F1000Research · doi:10.12688/f1000research.9970.1 · Cited by 481
Moradi, S. V., Hussein, W. M., Varamini, P., Simerska, P., & Toth, I. (2016) · Chemical Science · doi:10.1039/c5sc04392a · Cited by 286
Current strategies in extending half-lives of therapeutic proteins
Zaman, R., Islam, R. A., Ibnat, N., Othman, I., Zaini, A., Lee, C. Y., & Chowdhury, E. H. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.02.016 · Cited by 278
Glycosylation of extracellular vesicles: current knowledge, tools and clinical perspectives
Williams, C., Royo, F., Aizpurua‐Olaizola, O., Pazos, R., Boons, G., Reichardt, N., & Falcon‐Perez, J. M. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1442985 · Cited by 258
Recent advances in mammalian protein production
Bandaranayake, A. D., & Almo, S. C. (2014) · FEBS Letters · doi:10.1016/j.febslet.2013.11.035 · Cited by 222
Metadata
- Authors
- Costa, A. R., Rodrigues, M. E., Henriques, M., Oliveira, R., & Azeredo, J.
- Venue
- Critical Reviews in Biotechnology
- Publisher
- Informa UK Limited
- Published
- 2013-08-06
- Volume
- 34
- Issue
- 4
- Pages
- 281-299
- ISSN
- 0738-8551 (ISSN-L)
- 1549-7801
- OpenAlex
- W2031893105
- Cited by
- 155
- References
- 24
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glycosylation: impact, control and improvement during therapeutic protein production. https://app.cochat.ai/papers/10.3109/07388551.2013.793649
- The paper
- Costa, A. R., Rodrigues, M. E., Henriques, M., Oliveira, R., & Azeredo, J. (2014). Glycosylation: impact, control and improvement during therapeutic protein production. Critical Reviews in Biotechnology. https://doi.org/10.3109/07388551.2013.793649
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.